Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

By /

Aadi Bioscience, Inc. announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor had gynecologic origins experienced efficacy and safety consistent with the overall study population.

Scroll to Top